Irene Solia

MD, PhDc
Hematology Resident

[Thanos Dimopoulos @thanosdimop]

Our center was the top recruiting site in this practice changing study! https://t.co/OsaAGgdBlr

[onea @o_n_e_a]

With great pleasure, we announce the establishment of the Hellenic Group of Young Hematologists (YoungHSH)! We invite you to follow us and actively participate in strengthening the scientific training, networking, and active involvement of young hematologists
#hematology #onea

[onea @o_n_e_a]

Με ιδιαίτερη χαρά ανακοινώνουμε τη σύσταση της Ο.Ν.Ε.Α.! Σας προσκαλούμε να ακολουθήσετε και να συμμετέχετε ενεργά στην ενίσχυση της επιστημονικής κατάρτισης, της δικτύωσης και της ενεργούς συμμετοχής των νέων αιματολόγων.
#hematology #younghsh #onea #ΕλληνικήΑιματολογικήΕταιρεία

[Despina Fotiou @despina_fotiou]

Με ιδιαίτερη χαρά ανακοινώνουμε τη σύσταση της Ο.Ν.Ε.Α.! Σας προσκαλούμε να ακολουθήσετε και να συμμετέχετε ενεργά στην ενίσχυση της επιστημονικής κατάρτισης, της δικτύωσης και της ενεργούς συμμετοχής των νέων αιματολόγων.
@o_n_e_a #onea

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #IMS26 | PRESENTATION

Evangelos Terpos, National and Kapodistrian University of Athens, presented results from the multicenter, open-label, phase II EAE116 trial evaluating Isa-VCd induction followed by Isa-R maintenance in patients with NDMM and severe renal impairment (N = 51).

Among evaluable patients (n = 50), 88% achieved a hematologic ORR, with a median time to first response of 1 month. Among renal-response-evaluable patients (n = 49), 75.5% achieved ≥MRR and 38.8% achieved ≥PR. The median time to best renal response was 2.4 months and the median time to ≥MR was 1.1 months. MRD negativity was achieved in 72% of evaluable patients (n = 25). Dialysis independence was achieved in >50% of patients who were dialysis-dependent at baseline. TEAEs occurred in 88.2% of patients (Grade ≥3, 41.2%; Grade 5, 21.6%).

Follow our live feed for more updates: https://t.co/OZWuHVlO9d

Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.

#MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @uoaofficial

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #IMS26 | PRESENTATION

Meletios Dimopoulos, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, presented long-term results of the randomized phase III DREAMM-8 trial evaluating BPd (n = 155) vs PVd (n = 147) in patients with RRMM who had received ≥1 prior line of therapy.

At a median follow-up of 35.8 months, patients receiving BPd were >4 times more likely to achieve ≥ CR + MRD negativity (27.7% vs 6.1%) and >5 times more likely to achieve MRD negativity sustained ≥12 months (15.5% vs 2.7%) than those receiving PVd. Sustained MRD negativity was associated with durable PFS and PFS2 in both treatment groups.

Follow our live feed for more updates: https://t.co/OZWuHVlO9d

Intended for HCPs. This congress coverage is independently supported through funding from pharmaceutical companies. A full list of our funders can be found on our website. Funders are allowed no influence.

#MultipleMyeloma #myeloma #mmsm #MedEd #MedicalCongress @thanosdimop

[Thanos Dimopoulos @thanosdimop]

https://t.co/J8te4UqI7I

[Thanos Dimopoulos @thanosdimop]

Last day of the 23rd International Myeloma Society congress I will present the long term outcomes with sustained MRD negativity of patients treated with belamaf pomalidomide dexamethasone DREAMM 8 study

[Irene Solia @eirsolia]

The results from the EXCALIBER study presented at Glasgow #IMS2026, with important Greek contribution of the Professors Maria Gavriatopoulou @mgavriatopoulou and Thanos Dimopoulos @thanosdimop #MultipleMyeloma @UoATherapeutics

[Myeloma Society @Myeloma_Society]

There is a BCMA therapy for everyone, whether that be a CAR-T, a bispecific, or an ADC - there is an evidence gap around optimal sequencing and risk/molecular profile-based personalization of these therapies. --- Debate Session at #IMS26

[NEJM @NEJM]

Drs. Tarek H. Mouhieddine and Kenneth C. Anderson summarize treatment for multiple myeloma, highlighting four-drug induction therapy, evolving transplantation strategies, tailored maintenance therapy, and in relapse, earlier use of BCMA-directed immunotherapy.

Read the Review Article “Treatment Decisions in Multiple Myeloma”: https://t.co/rtFssp5gYf

[Vincent Rajkumar @VincentRK]

Our one stop place to calculate risk stratification of myeloma, smoldering myeloma (SMM), MGUS, amyloidosis and Waldenstrom Macroglobulinemia.
@myelomaMD @eamadoutoure

Check it out and bookmark!
https://t.co/8e2dLjpXZg

[Multiple Myeloma Hub @MM_Hub]

🚨 NEWS 🚨

@Saudi_FDA approves iberdomide, an oral CELMoD, in combination with daratumumab + dexamethasone for the treatment of RRMM, marking the first regulatory approval globally for a CELMoD in #MultipleMyeloma.

Read more: https://t.co/FPwsLLVoKt

#myeloma #mmsm #MedEd #MedNews

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Validation of IMS/IMWG consensus genomic staging in Greek cohort of 1209 pts finds high-risk has inferior outcomes (median OS 44 vs 93 months; PFS 21.3 vs 36); ≥2 high-risk features = ultra-high w/ 3-fold risk of death: https://t.co/h9lZyOfstx. #mmsm

[Vincent Rajkumar @VincentRK]

I am worried about the exploding number of “monoclonal gammopathy of clinical significance” entities. MGNS, MGRS, MGDS, MGTS etc

It’s time to become strict with diagnosis of these disorders. MGUS is now more common because everyone is using very sensitive tests. Add to this some researchers saying you don’t even need a clone or M protein to diagnosis this. I disagree.

Even for the most well documented MGCS entity, PGNMID if there is no M protein, whatever you see on the renal biopsy is most likely driven by some oligoclonal process not monoclonal. So, no M protein, no MGCS/MGRS should be the default.

Over diagnosis and trying to eradicate the M protein is far more dangerous than under diagnosis. So you need a level of proof or compelling evidence that it’s the M protein that’s causing the problem. If that’s difficult to establish then it’s on us to get the testing right. Otherwise except for like established syndromes like POEMS, we need this rigor. Some entities like AL amyloidosis, cryo, PGNMID etc routine available testing gives the proof we need. Some others especially neuropathy and clots, are so common and so many causes, we simply need a very high bar for diagnosis. See our paper here: https://t.co/tRSllzGlL2

[Daniel Auclair @AuclairDan]

Tec+Talq MonumenTAL-6, HR=0.11!! Drop the mic. Congrats to all involved! #mmsm

https://t.co/5nplxrus8S

[Thanos Dimopoulos @thanosdimop]

British Journal of Haematology | https://t.co/90wzIL7AFI

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Younger pts w/ asymptomatic monoclonal gammopathies exhibit similar biological features vs. older pts & generally low progression rates, suggesting early detection & low risk of complications with protocolized follow-up: https://t.co/P6O7liUqfs. #mmsm

[JohnNtan @johnntanasis]

Late-breaking SUCCESSOR-2 results presented by @thanosdimop @UoATherapeutics #EHA2026
https://t.co/o5S1Y04Dll

[Thanos Dimopoulos @thanosdimop]

The 7th European Myeloma Network meeting took place this week in Prague.I am very proud for our group with Drs Terpos,Kastritis and Gavriatopoulou giving lectures EMN is contributing significantly to the progress of myeloma treatment